MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Evolus, Inc. - Common Stock (NQ:EOLS)

5.650 -0.090 (-1.57%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Evolus, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
News headline image
4 Analysts Have This To Say About Evolus ↗
 
Via Benzinga
News headline image
Nasdaq Jumps 100 Points; Charles Schwab Profit Beats Estimates ↗
 
Via Benzinga
News headline image
Crude Oil Down 2%; D.R. Horton Earnings Top Views ↗
 
Via Benzinga
News headline image
A Closer Look at 5 Analyst Recommendations For Evolus ↗
 
Via Benzinga
News headline image
Analyst Scoreboard: 4 Ratings For Evolus ↗
 
Via Benzinga
News headline image
Evolus, An AbbVie And Botox Rival, Just Hit The Stratosphere — Here's Why ↗
The company expects to soon expand from a single-product player to a "multi-product innovator." 
Via Investor's Business Daily
News headline image
Charles Schwab Posts Upbeat Earnings, Joins Redwire, Evolus, Replimune Group And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Net Revenue, Achieving Record Results at the Top of the Company’s Guidance
From Evolus
Via Business Wire
News headline image
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
News headline image
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
News headline image
Evolus Reports Third Quarter 2024 Results
From Evolus
Via Business Wire
News headline image
Evolus to Participate in Stifel 2024 Healthcare Conference
From Evolus
Via Business Wire
News headline image
Evolus Announces EU Approval of Estyme® Injectable Hyaluronic Acid Gels Under New Medical Device Regulation
From Evolus
Via Business Wire
News headline image
Evolus Rewards™ Patient Loyalty Program Surpasses 1 Million Enrolled Consumers
From Evolus, Inc.
Via Business Wire
News headline image
Evolus to Report Third Quarter Financial Results on November 6, 2024
From Evolus
Via Business Wire
News headline image
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
News headline image
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
News headline image
Evolus to Ring the Nasdaq Stock Market Closing Bell on Friday, September 13, 2024
From Evolus
Via Business Wire
News headline image
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
News headline image
EOLS Stock Earnings: Evolus Misses EPS, Beats Revenue for Q2 2024 ↗
EOLS stock results show that Evolus missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Evolus, A Medical Aesthetics Player, Becomes Profitable — Two Quarters Early ↗
The company reported $1.1 million in adjusted operating income, well ahead of expectations for a $2.6 million loss. 
Via Investor's Business Daily
News headline image
Evolus Reports Second Quarter 2024 Results and Raises Full Year Revenue Guidance
From Evolus
Via Business Wire
News headline image
Evolus to Hold Investor Day on September 12, 2024
From Evolus
Via Business Wire
News headline image
Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in Australia
From Evolus, Inc.
Via Business Wire
News headline image
Evolus to Participate in the Canaccord Genuity 44th Annual Growth Conference
From Evolus
Via Business Wire
News headline image
Evolus to Report Second Quarter Financial Results on July 31, 2024
From Evolus
Via Business Wire
News headline image
Evolus Announces Appointment of Albert G. White III to Board of Directors
From Evolus
Via Business Wire
News headline image
Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products
From Evolus
Via Business Wire
News headline image
Evolus Broadens International Presence with Launch of Nuceiva® (botulinum toxin type A) in Spain
From Evolus
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story